Pain Therapeutics (PTIE) 4.70 $PTIE
Pain Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Thu May 08, 8:31AM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today announced that management will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The Company will present on Tuesday, May 13, 2014 at 3:00 p.m. Pacific Daylight Time at the Encore at Wynn in Las Vegas, NV.
Shares of PTIE Up 70.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed May 07, 9:08AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 9 months, Pain Therapeutics has returned 70.77% as of today's recent price of $5.20.
Pain Therapeutics Reports Q1 2014 Financial Results
GlobeNewswire - Tue May 06, 9:16AM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) today reported financial results for Q1 2014. Net loss in Q1 2014 was $3.5 million, or $0.08 per share, compared to a net loss in Q1 2013 of $0.4 million, or $0.01 per share. Net cash used in Q1 2014 was $2.7 million. At March 31, 2014, cash and investments were $47.1 million. As previously disclosed, the Company believes net cash usage for 2014 may be approximately $12 million.
Pain Therapeutics to Host Conference Call to Discuss Q1 2014 Financial Results
GlobeNewswire - Wed Apr 30, 3:30PM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) will host a conference call on Tuesday, May 6 at 3:30 p.m. Central Time/4:30 p.m. Eastern Time to discuss Q1 2014 financial results and provide an update on the Company.
Pain Therapeutics Shares Up 82.9% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Tue Apr 29, 5:14PM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 82.92% as of today's recent price of $5.57.
Research and Markets: Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
Business Wire - Mon Apr 28, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h3hqmg/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering.
Research and Markets: Global Neuropathic Pain Therapeutics Pipeline Review 2014
Business Wire - Mon Apr 28, 5:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6ccfgh/neuropathic_pain) has announced the addition of the "Neuropathic Pain - Pipeline Review, H1 2014" report to their offering.
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Global Neuropathic Pain Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zzckxs/neuropathic_pain) has announced the addition of the "Neuropathic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuropathic Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages For more information visit http://www.researchandmarkets.com/research/zz...athic_pain
Theralase Could Light Up Cancer Therapeutics
ACCESSWIRE - Thu Apr 24, 9:27AM CDT
Whitefish, MT / April 24, 2014 / Cancer patients don't have many good treatment options. Once the disease is detected, most oncologists will surgically remove as much as possible and then use powerful radiation and chemotherapy to kill as many cells in those areas as possible. The side effects from these treatments can be terrible and patients are at a higher risk of additional complications given the weakened state of the immune system.
Shares of PTIE Up 85.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 22, 10:56AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 85.22% as of today's recent price of $5.64.
Pain Therapeutics Shares Up 71.4% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Tue Apr 15, 9:40AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 71.43% as of today's recent price of $5.22.
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire Europe - Tue Apr 08, 8:00AM CDT
Research and Markets ( http://www.researchandmarkets.com/research/33...rapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/33sf9j/pain_therapeutics ] to their offering.
GW Pharmaceuticals talk Cannabinoids
PRWeb - Mon Apr 07, 12:18PM CDT
The industry established Pain Therapeutics conference for combining new pain therapeutic developments with essential networking and collaboration opportunities, will be taking place on 19th and 20th May at the Holiday Inn Kensington Forum, London.
Pain Therapeutics Has Returned 79.0% Since SmarTrend Recommendation (PTIE)
Comtex SmarTrend(R) - Mon Mar 31, 4:43PM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 78.98% as of today's recent price of $5.45.
Janssen Pharmaceutical to Provide Exclusive Update on Fulranumab Clinical Development
PRWeb - Thu Mar 20, 9:42AM CDT
SMi Group have worked together with an esteemed panel of speakers including KOLs from Merck, Janssen Pharmaceuticals, Imperial College London, Mundipharma, Nektar Pharmaceuticals, Morpheus and Eli Lilly, to put together the conference agenda for the 14th annual Pain Therapeutics event taking place on 19th and 20th May in Central London.
Pain Therapeutics Up 83.6% Since SmarTrend Uptrend Call (PTIE)
Comtex SmarTrend(R) - Mon Mar 17, 9:36AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 83.58% as of today's recent price of $5.59.
Pain Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Thu May 08, 8:31AM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today announced that management will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The Company will present on Tuesday, May 13, 2014 at 3:00 p.m. Pacific Daylight Time at the Encore at Wynn in Las Vegas, NV. Shares of PTIE Up 70.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed May 07, 9:08AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 9 months, Pain Therapeutics has returned 70.77% as of today's recent price of $5.20. Pain Therapeutics Reports Q1 2014 Financial Results
GlobeNewswire - Tue May 06, 9:16AM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today reported financial results for Q1 2014. Net loss in Q1 2014 was $3.5 million, or $0.08 per share, compared to a net loss in Q1 2013 of $0.4 million, or $0.01 per share. Net cash used in Q1 2014 was $2.7 million. At March 31, 2014, cash and investments were $47.1 million. As previously disclosed, the Company believes net cash usage for 2014 may be approximately $12 million. Pain Therapeutics to Host Conference Call to Discuss Q1 2014 Financial Results
GlobeNewswire - Wed Apr 30, 3:30PM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) will host a conference call on Tuesday, May 6 at 3:30 p.m. Central Time/4:30 p.m. Eastern Time to discuss Q1 2014 financial results and provide an update on the Company. Pain Therapeutics Shares Up 82.9% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Tue Apr 29, 5:14PM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 82.92% as of today's recent price of $5.57. Research and Markets: Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
Business Wire - Mon Apr 28, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h3hqmg/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering.
Research and Markets: Global Neuropathic Pain Therapeutics Pipeline Review 2014
Business Wire - Mon Apr 28, 5:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6ccfgh/neuropathic_pain) has announced the addition of the "Neuropathic Pain - Pipeline Review, H1 2014" report to their offering.
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Global Neuropathic Pain Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zzckxs/neuropathic_pain) has announced the addition of the "Neuropathic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuropathic Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages For more information visit http://www.researchandmarkets.com/research/zz...athic_pain
Theralase Could Light Up Cancer Therapeutics
ACCESSWIRE - Thu Apr 24, 9:27AM CDT
Whitefish, MT / April 24, 2014 / Cancer patients don't have many good treatment options. Once the disease is detected, most oncologists will surgically remove as much as possible and then use powerful radiation and chemotherapy to kill as many cells in those areas as possible. The side effects from these treatments can be terrible and patients are at a higher risk of additional complications given the weakened state of the immune system.
Shares of PTIE Up 85.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 22, 10:56AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 85.22% as of today's recent price of $5.64. Pain Therapeutics Shares Up 71.4% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Tue Apr 15, 9:40AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 71.43% as of today's recent price of $5.22. Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire Europe - Tue Apr 08, 8:00AM CDT
Research and Markets ( http://www.researchandmarkets.com/research/33...rapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/33sf9j/pain_therapeutics ] to their offering.
GW Pharmaceuticals talk Cannabinoids
PRWeb - Mon Apr 07, 12:18PM CDT
The industry established Pain Therapeutics conference for combining new pain therapeutic developments with essential networking and collaboration opportunities, will be taking place on 19th and 20th May at the Holiday Inn Kensington Forum, London.
Pain Therapeutics Has Returned 79.0% Since SmarTrend Recommendation (PTIE)
Comtex SmarTrend(R) - Mon Mar 31, 4:43PM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 78.98% as of today's recent price of $5.45. Janssen Pharmaceutical to Provide Exclusive Update on Fulranumab Clinical Development
PRWeb - Thu Mar 20, 9:42AM CDT
SMi Group have worked together with an esteemed panel of speakers including KOLs from Merck, Janssen Pharmaceuticals, Imperial College London, Mundipharma, Nektar Pharmaceuticals, Morpheus and Eli Lilly, to put together the conference agenda for the 14th annual Pain Therapeutics event taking place on 19th and 20th May in Central London.
Pain Therapeutics Up 83.6% Since SmarTrend Uptrend Call (PTIE)
Comtex SmarTrend(R) - Mon Mar 17, 9:36AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 83.58% as of today's recent price of $5.59. 
